CORCEPT THERAPEUTICS INCORPORATED - COMMON STOCK

NetDania - New 12 months High: CORCEPT THERAPEUTICS INCORPORATED - COMMON STOCK

25 يوليو 2024 10:29:14 بحسب NetDania Notify

Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call

22 يوليو 2024 15:05:00 بحسب Nasdaq GlobeNewswire

Corcept Announces Presentation of Results From Prevalence Phase of CATALYST Clinical Trial at American Diabetes Association’s Scientific Sessions

24 يونيو 2024 15:15:00 بحسب Nasdaq GlobeNewswire

NetDania - New 12 months High: CORCEPT THERAPEUTICS INCORPORATED - COMMON STOCK

06 يونيو 2024 08:45:18 بحسب NetDania Notify

NetDania - New 12 months High: CORCEPT THERAPEUTICS INCORPORATED - COMMON STOCK

05 يونيو 2024 12:50:40 بحسب NetDania Notify

Corcept Therapeutics Announces Presentations of Results of Pivotal Phase 3 GRACE Trial Evaluating Relacorilant in Patients with Hypercortisolism (Cushing’s Syndrome)

03 يونيو 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Corcept Announces Primary Endpoint Met in Pivotal Phase 3 GRACE Trial of Relacorilant in Patients With Hypercortisolism (Cushing’s Syndrome)

28 مايو 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Corcept Therapeutics Announces First Quarter Financial Results and Provides Corporate Update

01 مايو 2024 15:05:00 بحسب Nasdaq GlobeNewswire

Corcept Completes Enrollment in Phase 4 CATALYST Trial

29 أبريل 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call

24 أبريل 2024 15:05:00 بحسب Nasdaq GlobeNewswire

NetDania - New 12 months Low: CORCEPT THERAPEUTICS INCORPORATED - COMMON STOCK

22 أبريل 2024 08:59:41 بحسب NetDania Notify

Corcept Announces Positive Results From Open-Label Portion of Pivotal Phase 3 GRACE Trial in Patients With Cushing’s Syndrome

22 أبريل 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Corcept Completes Enrollment in Phase 2 DAZALS Trial in Patients With Amyotrophic Lateral Sclerosis (ALS)

15 أبريل 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Corcept Completes Enrollment in Pivotal Phase 3 Rosella Trial of Relacorilant in Patients With Platinum-Resistant Ovarian Cancer

08 أبريل 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Corcept Completes Enrollment in Phase 3 Gradient Trial of Relacorilant in Patients With Adrenal Cushing’s Syndrome

01 أبريل 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Corcept Therapeutics Announces Fourth Quarter and Full-Year 2023 Audited Financial Results and Provides Corporate Update

15 فبراير 2024 15:07:00 بحسب Nasdaq GlobeNewswire

Corcept Announces Preliminary Results From Prevalence Phase Of CATALYST Clinical Trial

15 فبراير 2024 15:02:00 بحسب Nasdaq GlobeNewswire

Corcept Therapeutics to Announce Fourth Quarter and Full-Year 2023 Financial Results, Provide Corporate Update and Host Conference Call

08 فبراير 2024 15:05:00 بحسب Nasdaq GlobeNewswire

Corcept Appoints Roberto Vieira as President, Oncology

29 يناير 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Corcept Therapeutics Provides Financial Update and Announces Stock Repurchase Program

08 يناير 2024 07:00:01 بحسب Nasdaq GlobeNewswire